Cell fast chemical reprogramming technique
By using specific small molecule combinations and multi-stage medium design, the cell chemical reprogramming time is shortened and efficiency is improved, and the problem of inefficiency in the prior art is solved, achieving efficient conversion of fibroblasts into induced pluripotent within 7 days Stem cell method.
Patent Information
- Application Number
- PCT/CN2024/098193
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-07
- Filing Date
- 2024-06-07
- Publication Date
- 2024-12-12
AI Technical Summary
In the prior art, the cytochemical reprogramming process takes a long time and is less efficient. Only about 20-30 induced pluripotent stem cell clones can be formed in about 20 days, and the efficiency is low.
Using a chemical reprogramming promoter combination containing small molecules such as SR11237, CD3254, CCT129202, R406, DMH1, BML-277, AZD9291 mesylate, TSA, SGC-CBP30, Citarinostat, TMP269, WS6, etc., through the design of multi-stage culture medium , shorten the chemical reprogramming time to 7 days and increase the number of induced pluripotent stem cell clones per 10,000 initial cells to 40-90.
The chemical reprogramming process is significantly shortened and the efficiency is improved by 10 times. 40-90 induced pluripotent stem cell clones can be formed per 10,000 initial cells, which is suitable for a variety of mouse cell types and genetic backgrounds.
Smart Images

Figure PCTCN2024098193-FTAPPB-I100001 
Figure PCTCN2024098193-FTAPPB-I100002 
Figure PCTCN2024098193-FTAPPB-I100003
Abstract
Description
Rapid chemical cell reprogramming technology Technical Field
[0001] The present invention relates to the field of induced pluripotent stem cells, and in particular to a technology for rapid chemical reprogramming of cells. Background Art
[0002] Small molecules can be used to promote the reprogramming of somatic cells into induced pluripotent stem cells (iPSCs). In 2013, the technology of using small molecules to reprogram somatic cells into induced pluripotent stem cells (iPSCs) was first reported by Deng Hongkui's research group. The small molecules used were VPA, CHIR99021, RepSox, Forskolin, Tranylcypromine and DZNep. This technology is called chemical reprogramming. The earliest chemical reprogramming technology required about 60 days to achieve this process (Hou PP, et al., Pluripotent Stem Cells Induced from Mouse Somatic Cells by Small-Molecule Compounds. Science, 2013. 341(6146): p.651-54.). Since then, there have been three reports on the main progress of this technology improvement. First, in 2015, Deng Hongkui's group added four small molecules, AM580, EPZ004777, SGC0946 and 5-aza-dc, to this reprogramming system, shortening the chemical reprogramming process to about 40 days (Zhao Y., et al., A XEN-like State Bridges Somatic Cells to Pluripotency during Chemical Reprogramming. Cell, 2015. 163(7): p. 1678-91.); Second, in 2018, Pei Duanqing's group independently established a chemical reprogramming system, which also took about 40 days to complete the process, which was more efficient than the report of Deng Hongkui's group in 2015 (Cao S., et al., Chromatin Accessibility Dynamics during Chemical Induction of Pluripotency. Cell Stem Cell, 2015. 163(7): p. 1678-91.). Cell, 2018.22(4):p.529-42e5.); Third, in 2018, Deng Hongkui's research group further optimized the 2015 chemical reprogramming system and shortened the time to about 20 days, but the efficiency of forming induced pluripotent stem cells was low (Zhao T., et al., Single-Cell RNA-Seq Reveals Dynamic Early Embryonic-like Programs during Chemical Reprogramming. Cell Stem Cell, 2018.23(1):p.31-+.). After 2018, no faster and more efficient technologies have been reported in this field.
[0003] Existing technologies require a long time to complete the entire chemical reprogramming process. The most efficient techniques require approximately 40 days to complete. Techniques that can complete chemical reprogramming in around 20 days are less efficient, for example, only generating approximately 20-30 induced pluripotent stem cell clones for every 50,000 initial cells.
[0004] Therefore, there is a need in the art to provide an efficient and rapid cell chemical reprogramming technology.
[0005] Summary of the Invention
[0006] The purpose of the present invention is to provide a rapid cell chemical reprogramming technology.
[0007] In the first aspect of the present invention, a chemical reprogramming accelerator is provided, wherein the chemical reprogramming accelerator is selected from the following group A:
[0008] (A1)SR11237;
[0009] (A2)CD3254;
[0010] (A3)CCT129202;
[0011] (A4)R406;
[0012] (A5)DMH1;
[0013] (A6) BML-277;
[0014] (A7)AZD9291 mesylate;
[0015] (A8)TSA;
[0016] (A9)SGC-CBP30
[0017] (A10) Citarinostat;
[0018] (A11)TMP269;
[0019] (A12)WS6;
[0020] (A13) Any combination of (A1) to (A12).
[0021] In another preferred embodiment, the chemical reprogramming accelerator is a compound selected from the following group:
[0022] (1)SR11237,CD3254;
[0023] (2) CCT129202, R406;
[0024] (3)DMH1, BML-277, AZD9291 mesylate, TSA, SGC-CBP30, Citarinostat;
[0025] (4)DMH1, BML-277, AZD9291 mesylate, TSA, TMP269; and
[0026] (5)WS6.
[0027] In another preferred embodiment, in the reprogramming medium, the chemical reprogramming promoter has a concentration selected from the following group:
[0028] SR11237: 0.05-0.5 μM;
[0029] CD3254: 0.05-0.5 μM;
[0030] CCT129202: 0.2-2 μM;
[0031] R406: 0.5-2 μM;
[0032] DMH1: 0.1-5 μM;
[0033] BML-277: 5-20 μM;
[0034] AZD9291 mesylate: 1-5 μM;
[0035] TSA: 5-20nM;
[0036] SGC-CBP30: 0.5-5 μM;
[0037] Citarinostat: 1-3 μM;
[0038] TMP269: 1-10 μM;
[0039] WS6: 0.1-2 μM.
[0040] In a second aspect of the present invention, there is provided a use of a chemical reprogramming accelerator for preparing a reagent or kit for converting fibroblasts into induced pluripotent stem cells; wherein the chemical reprogramming accelerator is selected from the following group:
[0041] (A1)SR11237;
[0042] (A2)CD3254;
[0043] (A3)CCT129202;
[0044] (A4)R406;
[0045] (A5)DMH1;
[0046] (A6) BML-277;
[0047] (A7)AZD9291 mesylate;
[0048] (A8)TSA;
[0049] (A9)SGC-CBP30
[0050] (A10) Citarinostat;
[0051] (A11)TMP269;
[0052] (A12)WS6;
[0053] (A13) Any combination of (A1) to (A12).
[0054] In another preferred embodiment, the fibroblasts are mammalian fibroblasts; preferably, they are fibroblasts from mice, rats, rabbits, monkeys, or humans.
[0055] In another preferred embodiment, the fibroblasts are mouse fibroblasts, preferably mouse dorsal fibroblasts (MDF), mouse lung fibroblasts (MLF), mouse liver fibroblasts, mouse cardiac fibroblasts or mouse embryonic fibroblasts (MEF).
[0056] In a third aspect of the present invention, a culture medium for chemical reprogramming is provided, comprising basic culture components and a chemical reprogramming promoter, wherein the chemical reprogramming promoter is selected from the following group A:
[0057] (A1)SR11237;
[0058] (A2)CD3254;
[0059] (A3)CCT129202;
[0060] (A4)R406;
[0061] (A5)DMH1;
[0062] (A6) BML-277;
[0063] (A7)AZD9291 mesylate;
[0064] (A8)TSA;
[0065] (A9)SGC-CBP30
[0066] (A10) Citarinostat;
[0067] (A11)TMP269;
[0068] (A12)WS6;
[0069] (A13) Any combination of (A1) to (A12).
[0070] In another preferred embodiment, the basic culture components include basic culture medium, serum or serum substitute, non-essential amino acid solution, penicillin / streptomycin mixture, 1×N2 additive, 1×B27 additive, glutamine substitute solution or Vc.
[0071] In another preferred embodiment, the basic culture medium is selected from the following group: DMEM basic culture medium, Neurobasal culture medium, or DMEM / F12 culture medium.
[0072] In another preferred embodiment, the culture medium for chemical reprogramming further comprises other growth factors and compounds, including but not limited to: β-mercaptoethanol, basic fibroblast growth factor, CHIR99021, 616452, Forskolin, AM580, EPZ004777, VPA, 5-aza-dC, SGC0946, mouse leukemia inhibitory factor, and PD0325901.
[0073] In a fourth aspect of the present invention, a method for reprogramming fibroblasts into induced pluripotent stem cells is provided, comprising:
[0074] (S1) providing a fibroblast;
[0075] (S2) pre-culturing the fibroblasts in (S1) using a first reprogramming cell culture medium to obtain first intermediate cells;
[0076] (S3) culturing the first intermediate cells using a second reprogramming cell culture medium to obtain second intermediate cells;
[0077] (S4) culturing the second intermediate cells using a third reprogramming cell culture medium to obtain third intermediate cells;
[0078] (S5) culturing the third intermediate cell using a fourth reprogramming cell culture medium to obtain a fourth intermediate cell; and
[0079] (S6) Expanding the fourth intermediate cells to obtain induced pluripotent stem cells.
[0080] In another preferred embodiment, in (S1), the density of the fibroblasts is 10 4 -106 cells / well.
[0081] In another preferred embodiment, in (S2), the first reprogramming cell culture medium comprises a compound selected from the following group: SR11237, CD3254.
[0082] In another preferred embodiment, in (S2), the first reprogramming cell culture medium further comprises a compound selected from the following group: basic fibroblast growth factor, CHIR99021, 616452, Forskolin, AM580, EPZ004777.
[0083] In another preferred embodiment, in (S2), the concentration of SR11237 is 0.05-0.5 μM;
[0084] In another preferred embodiment, in (S2), the concentration of CD3254 is 0.05-0.5 μM.
[0085] In another preferred embodiment, in (S2), the culture time is t1, and t1 is 0-3 days; preferably 0.5-2 days.
[0086] In another preferred embodiment, in (S3), the second reprogramming cell culture medium comprises a compound selected from the following group: CCT129202, R406.
[0087] In another preferred embodiment, in (S3), the second reprogramming cell culture medium further comprises a compound selected from the following group: basic fibroblast growth factor, CHIR99021, 616452, Forskolin, AM580, SR11237, CD3254, VPA.
[0088] In another preferred embodiment, in (S3), the concentration of CCT129202 is 0.2-2 μM.
[0089] In another preferred embodiment, in (S3), the concentration of R406 is 0.5-2 μM.
[0090] In another preferred embodiment, in (S3), the culture time is t2, and t2 is 0-3 days; preferably 0.5-2 days.
[0091] In another preferred embodiment, in (S4), the third reprogramming cell culture medium comprises a compound selected from the group consisting of DMH1, BML-277, AZD9291 mesylate, TSA, SGC-CBP30, and Citarinostat.
[0092] In another preferred embodiment, in (S4), the third reprogramming cell culture medium further comprises a compound selected from the following group: basic fibroblast growth factor, CHIR99021, 616452, 5-aza-dC, and SGC0946.
[0093] In another preferred embodiment, in (S4), the concentration of DMH1 is 0.1-5 μM;
[0094] The concentration of BML-277 was 5–20 μM;
[0095] The concentration of AZD9291 mesylate was 1–5 μM;
[0096] The concentration of TSA was 5–20 nM;
[0097] The concentration of SGC-CBP30 was 1–10 μM;
[0098] The concentration of citarinostat was 1-3 μM.
[0099] In another preferred embodiment, in (S4), the culture time is t3, and t3 is 0-3 days; preferably 0.5-2 days.
[0100] In another preferred embodiment, in (S5), the fourth reprogramming cell culture medium comprises a compound selected from the group consisting of DMH1, BML-277, AZD9291 mesylate, TSA, and TMP269.
[0101] In another preferred embodiment, in (S5), the fourth reprogramming cell culture medium further comprises a compound selected from the following group: basic fibroblast growth factor, mouse leukemia inhibitory factor, CHIR99021, 616452, 5-aza-dC.
[0102] In another preferred embodiment, in (S5), the concentration of DMH1 is 0.1-5 μM;
[0103] The concentration of BML-277 was 5–20 μM;
[0104] The concentration of AZD9291 mesylate was 1–5 μM;
[0105] The concentration of TSA was 5–20 nM;
[0106] The concentration of TMP269 was 1-10 μM.
[0107] In another preferred embodiment, in (S5), the culture time is t3, and t3 is 0-3 days; preferably 0.5-2 days.
[0108] In another preferred embodiment, the culture time of the fourth intermediate cells (S5) obtained from the fibroblast culture (S1) is 5-10 days, preferably 6-8 days.
[0109] In another preferred embodiment, (S6) includes:
[0110] The fourth intermediate cells are cultured using the fifth reprogramming cell culture medium to obtain fifth intermediate cells.
[0111] In another preferred example, the fifth reprogramming cell culture medium contains WS6.
[0112] In another preferred embodiment, (S6) further includes: culturing the fifth intermediate cells using a sixth reprogramming cell culture medium to obtain induced pluripotent stem cells.
[0113] In another preferred example, the sixth reprogramming cell culture medium comprises WS6.
[0114] In another preferred embodiment, in (S6), the fifth reprogramming cell culture medium further comprises a compound selected from the following group: mouse leukemia inhibitory factor, CHIR99021, 616452, Vc, PD0325901.
[0115] In another preferred embodiment, the sixth reprogramming cell culture medium further comprises a compound selected from the following group: mouse leukemia inhibitory factor, CHIR99021, Vc, and PD0325901.
[0116] In another preferred embodiment, in (S6), the concentration of WS6 is 0.1-2 μM.
[0117] In another preferred embodiment, in (S6), the culture time is t4, and t4 is 0-6 days, preferably 0.5-4 days.
[0118] In another preferred embodiment, the fibroblasts are mammalian fibroblasts; preferably, they are fibroblasts from mice, rats, rabbits, monkeys, or humans.
[0119] In another preferred embodiment, the fibroblasts are mouse fibroblasts, preferably mouse dorsal fibroblasts (MDF), mouse lung fibroblasts (MLF), mouse liver fibroblasts, mouse cardiac fibroblasts or mouse embryonic fibroblasts (MEF).
[0120] In a fifth aspect of the present invention, provided is an embryonic stem cell prepared by the method of the fourth aspect of the present invention, wherein the cell expresses the following markers: Oct4, Sox2, Rex1, Nanog.
[0121] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be listed here one by one. BRIEF DESCRIPTION OF THE DRAWINGS
[0122] Figure 1. (a) Schematic representation of the rapid chemical reprogramming (FCR) process, where iPSCs are generated within 12 days using different small molecule combinations every 2 days. (b) Scatter plot of changes in reprogramming efficiency after removing individual small molecules or growth factors every 2 days. Data are presented as mean ± SD. Biological replicates were performed in n = 3. C: CHIR99021; 6: 616452; F: Forskolin; A: AM580; E: EPZ004777; SR: SR11237; CD: CD3254; V: VPA; CCT: CCT129202; R: R406; D: 5-aza-dC; S: SGC0946; DMH: DMH1; BML: BML-277; AZD: AZD9291 mesylate; CBP: SGC-CBP30; Cit: Citarinostat; TMP: TMP269; WS: WS6; PD: PD0325901. (c) Images of pOct4-GFP (left), Oct4 immunofluorescence staining (center), and a merged image of pOct4-GFP, Oct4, and Hoechst staining (right) on days 8, 10, and 12 of FCR. Scale bar, 100 μm. (d) Line graph of iPSC colony numbers during FCR. Data are presented as mean ± SD. Biological replicates, n = 3.
[0123] Figure 2. (A) Images of iPSC lines established by rapid chemical reprogramming, with bright field on the left and green fluorescence on the right. Scale bar, 200 μm. (B) Images of iPSC immunofluorescence staining for the expression of the pluripotency genes Oct4, Nanog, and Sox2. Hoechst is a nuclear dye. Scale bar, 100 μm. (C) RT-qPCR results for MEFs, mouse embryonic stem cells (R1 mESCs), and three iPSC lines for the expression of the pluripotency genes Oct4, Nanog, Sox2, and Rex1. Data are presented as mean ± SD. Biological replicates, n = 3. (D) Volcano plots showing the relative expression of all genes in iPSCs compared to R1 mESCs (left panel) and iPSCs compared to MEFs (right panel). R, Pearson correlation coefficient.
[0124] Figure 3. (A) Brightfield images of 129×C57 MEFs and CF1 MEFs on day 0 and day 12 of rapid chemical reprogramming. (B) Immunofluorescence staining of Oct4 on day 12 of rapid chemical reprogramming of 129×C57 MEFs and CF1 MEFs. (C) Brightfield images of iPSC lines derived from 129×C57 MEFs and CF1 MEFs via rapid chemical reprogramming. (D) Immunofluorescence staining of Oct4, Nanog, and Sox2 in iPSC lines derived from 129×C57 MEFs and CF1 MEFs via rapid chemical reprogramming. Scale bars in all images are 200 μm.
[0125] Figure 4. (A) Brightfield images of MLFs derived from adult mice and MDFs derived from embryonic day 18.5. (B) Brightfield and pOct4-GFP fluorescence images of MLFs and MDFs at day 12 of rapid chemical reprogramming. (C) Brightfield and pOct4-GFP fluorescence images of iPSC cell lines derived from MLFs and MDFs via rapid chemical reprogramming. (D) Immunofluorescence staining of Oct4, Nanog, and Sox2 in iPSC cell lines derived from MLFs and MDFs via rapid chemical reprogramming. Scale bars in all images are 200 μm. DETAILED DESCRIPTION
[0126] After extensive and in-depth research, the inventors unexpectedly discovered for the first time that, using the chemical reprogramming accelerators of the present invention, the method of the present invention significantly shortens the time required for chemical reprogramming compared to the prior art; chemical reprogramming can be completed on the 7th day, and 40-90 induced pluripotent stem cell clones can be formed for every 10,000 initial cells; the reprogramming efficiency is increased by 10 times. Compared to the 20-day chemical reprogramming system, the method of the present invention can be applied to mouse cells with a wider range of genetic backgrounds and more types. This is based on the present invention.
[0127] the term
[0128] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0129] The term "about" can refer to a value or composition that is within an acceptable error range for the particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined.
[0130] As used herein, the terms "comprising" or "including" may be open, semi-closed, or closed. In other words, the terms also include "consisting essentially of" or "consisting of."
[0131] As used herein, the term "embryonic stem cells" refers to cells isolated from the inner cell mass of mouse blastocysts, which have the potential to differentiate into any cell type in the body.
[0132] As used herein, the term "induced pluripotent stem cells" refers to pluripotent stem cells derived from somatic cells by overexpressing transcription factors or using small molecules. These stem cells possess the potential to differentiate into any cell type in the body and therefore have enormous potential for application in drug screening, disease modeling, and regenerative medicine. Gene markers for induced pluripotent stem cells include Oct4, Nanog, Sox2, and Rex1.
[0133] As used herein, the term "pOct4-GFP" refers to the green fluorescent protein gene driven by the Oct4 gene promoter. When Oct4 is activated in cells, green fluorescent protein is produced, thereby allowing green fluorescence to be observed under a fluorescence microscope.
[0134] As used herein, the term "RT-qPCR" refers to a technique for detecting the expression level of a specific gene.
[0135] As used herein, the term "RNA-seq" refers to a technique that detects the expression levels of all genes in a cell.
[0136] Chemical reprogramming accelerator of the present invention
[0137] As used herein, the term "chemical reprogramming promoter" is used to promote the transformation of fibroblasts into induced pluripotent stem cells, and is preferably selected from the following group A:
[0138] (A1)SR11237;
[0139] (A2)CD3254;
[0140] (A3)CCT129202;
[0141] (A4)R406;
[0142] (A5)DMH1;
[0143] (A6) BML-277;
[0144] (A7)AZD9291 mesylate;
[0145] (A8)TSA;
[0146] (A9)SGC-CBP30
[0147] (A10) Citarinostat;
[0148] (A11)TMP269;
[0149] (A12)WS6;
[0150] (A13) Any combination of (A1) to (A12).
[0151] As described herein, the terms "the method of inducing pluripotent stem cells of the present invention," "the method of chemically reprogramming mouse fibroblasts of the present invention," and "the method of rapid chemical reprogramming (FCR) of the present invention" are used interchangeably and specifically refer to the method of the present invention using a chemical reprogramming promoter to promote the conversion of fibroblasts into induced pluripotent stem cells. Preferably, the method comprises:
[0152] (S1) providing a fibroblast;
[0153] (S2) pre-culturing the fibroblasts in (S1) using a first reprogramming cell culture medium to obtain first intermediate cells;
[0154] (S3) culturing the first intermediate cells using a second reprogramming cell culture medium to obtain second intermediate cells;
[0155] (S4) culturing the second intermediate cells using a third reprogramming cell culture medium to obtain third intermediate cells;
[0156] (S5) culturing the third intermediate cell using a fourth reprogramming cell culture medium to obtain a fourth intermediate cell; and
[0157] (S6) Expanding the fourth intermediate cells to obtain induced pluripotent stem cells.
[0158] Preferably, the first reprogramming cell culture medium comprises a chemical reprogramming promoter selected from the group consisting of SR11237, CD3254;
[0159] The second reprogramming cell culture medium contains a chemical reprogramming promoter selected from the group consisting of: CCT129202, R406;
[0160] The third reprogramming cell culture medium comprises a chemical reprogramming promoter selected from the group consisting of DMH1, BML-277, AZD9291 mesylate, TSA, SGC-CBP30, and Citarinostat;
[0161] The fourth reprogramming cell culture medium comprises a chemical reprogramming promoter selected from the group consisting of DMH1, BML-277, AZD9291 mesylate, TSA, and TMP269;
[0162] The fifth reprogramming cell culture medium comprises a chemical reprogramming promoter selected from the group consisting of WS6.
[0163] As used herein, the term "intermediate cells" refers to cells in an intermediate state obtained under different culture conditions during the process of culturing fibroblasts into induced pluripotent stem cells. Among them, the fourth intermediate cells express the mouse embryonic stem cell marker Oct4 to varying degrees.
[0164] The main advantages of the present invention include
[0165] (1) The present invention discovered for the first time that small molecules CCT129202, BML-277, TSA, DMH1, AZD9291mesylate, SGC-CBP30, TMP269, Citarinostat, and WS6 can promote the efficiency of chemical reprogramming.
[0166] (2) The method of the present invention can be applied to mouse embryonic fibroblasts, mouse dorsal fibroblasts, mouse liver fibroblasts, mouse cardiac fibroblasts and mouse lung fibroblasts.
[0167] (3) The method of the present invention can be applied to mouse embryonic fibroblasts with genetic backgrounds of 129XOG2, 129XC57 and CF1.
[0168] (4) The method of the present invention achieves highly efficient chemical reprogramming within 7-12 days, and 40-90 induced pluripotent stem cell clones can be formed for every 10,000 initial cells, which is 8-13 days faster than the technical solutions in the prior art and 10 times more efficient.
[0169] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples, for which detailed conditions are not specified, were generally performed under conventional conditions such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.
[0170] The name and structure of the compound involved in the present invention
[0171] Table 1
[0172] The method of fast chemical reprogramming (FCR) of the present invention
[0173] (1) Mouse embryonic fibroblasts (MEFs) with a genetic background of 129XOG2 were cultured at a rate of 2.5×10 5Cells were seeded into 6-well cell culture plates at a density of 100 cells / well and cultured overnight in MEF medium at 21% O2, 5% CO2, and 37°C.
[0174] (2) One day later, the cell culture medium was replaced with the rapid chemical reprogramming 0-2 day medium, which was recorded as reprogramming day 0.
[0175] (3) On the second day of reprogramming, the cell culture medium was replaced with the rapid chemical reprogramming 2-4 day medium.
[0176] (4) On the 4th day of reprogramming, the cell culture medium was replaced with the rapid chemical reprogramming 4-6 day medium, and the medium was renewed on the 5th day.
[0177] (5) On the 6th day of reprogramming, the cell culture medium was replaced with the rapid chemical reprogramming 6-8 day medium, and the medium was renewed on the 7th day.
[0178] (6) On the 8th day of reprogramming, the cell culture medium was replaced with the rapid chemical reprogramming 8-10 day medium.
[0179] (7) On the 10th day of reprogramming, the cell culture medium was replaced with the rapid chemical reprogramming 10-12 day medium.
[0180] (8) On the 12th day of reprogramming, the number of pluripotent stem cell clones was counted under a microscope based on GFP fluorescence.
[0181] The cells can also be passaged onto cell culture plates seeded with feeder cells to expand and obtain induced pluripotent stem cell lines.
[0182] The culture medium of the present invention is as follows:
[0183] MEF culture medium: DMEM basic medium (Gibco, Cat#11965092), 10% fetal bovine serum (v / v) (Gibco, Cat#10099), 1% penicillin / streptomycin mixture (v / v) (Gibco, Cat#15140163).
[0184] Rapid chemical reprogramming day 0-2 culture medium: DMEM basic medium, 10% fetal bovine serum (v / v), 10% serum replacement (v / v) (Gibco, Cat#10828028), 1% non-essential amino acid solution (v / v) (Cat#11140050), 1% penicillin / streptomycin mixture (v / v), 0.055 mM β-mercaptoethanol, 100 ng / mL basic fibroblast growth factor, 20 μM CHIR99021, 10 μM 616452, 50 μM Forskolin, 0.5 μM AM580, 0.1 μM SR11237, 0.1 μM CD3254, 5 μM EPZ004777.
[0185] Rapid chemical reprogramming 2-4 days culture medium: DMEM basic medium, 10% fetal bovine serum, 10% serum replacement, 1% non-essential amino acid solution, 1% penicillin / streptomycin mixture, 0.055mM β-mercaptoethanol, 100ng / mL basic fibroblast growth factor, 20μM CHIR99021, 10μM 616452, 50μM Forskolin, 0.5μM AM580, 0.1μM SR11237, 0.1μM CD3254, 0.2mM VPA, 0.5μM CCT129202, 1μM R406.
[0186] Rapid chemical reprogramming 4-6 days culture medium: DMEM basic medium, 10% fetal bovine serum, 10% serum replacement, 1% non-essential amino acid solution, 1% penicillin / streptomycin mixture, 0.055mM β-mercaptoethanol, 20ng / mL basic fibroblast growth factor, 10μM CHIR99021, 10μM 616452, 1μM DMH1, 10μM BML-277, 0.5μM 5-aza-dC, 5μM AZD9291 mesylate, 10nM TSA, 5μM SGC0946, 1μM SGC-CBP30, 2μM Citarinostat.
[0187] Rapid chemical reprogramming 6-8 days culture medium: DMEM basic medium, 10% fetal bovine serum, 10% serum replacement, 1% non-essential amino acid solution, 1% penicillin / streptomycin mixture, 0.055mM β-mercaptoethanol, 20ng / mL basic fibroblast growth factor, 1000U / mL mouse leukemia inhibitory factor, 10μM CHIR99021, 10μM 616452, 1μM DMH1, 10μM BML-277, 0.5μM 5-aza-dC, 5μM AZD9291 mesylate, 10nM TSA, 2μM TMP269.
[0188] Rapid chemical reprogramming 8-10 days culture medium: 47% DMEM / F12 medium (v / v) (Gibco, Cat#11320033), 47% Neurobasal medium (v / v) (Gibco, Cat#21103049), 1× N2 supplement (Gibco, Cat#17502048), 1× B27 supplement (Gibco, Cat#17504044), 1% glutamine substitute solution (v / v) (Gibco, Cat#35050079), 1% non-essential amino acid solution, 0.055 mM β-mercaptoethanol, 1% penicillin / streptomycin mixture, 1000 U / mL mouse leukemia inhibitory factor, 5 μM CHIR99021, 0.5 μM WS6, 250 μM Vc.
[0189] Rapid chemical reprogramming 10-12 days culture medium: 47% DMEM / F12 medium, 47% Neurobasal medium, 1× N2 supplement, 1× B27 supplement, 1% glutamine substitute solution, 1% non-essential amino acid solution, 0.055 mM β-mercaptoethanol, 1% penicillin / streptomycin mixture, 1000 U / mL mouse leukemia inhibitory factor, 2 μM CHIR99021, 0.5 μM WS6, 250 μM Vc, 1 μM PD0325901.
[0190] Example 1 Exploration of the effect of a single small molecule on reprogramming efficiency
[0191] 1.1 Effect of single small molecules on reprogramming efficiency
[0192] Mouse embryonic fibroblasts with a genetic background of 129XOG2 were used to detect changes in cell reprogramming efficiency after removing a single small molecule or growth factor every 2 days according to the rapid chemical reprogramming (FCR) method of the present invention.
[0193] Experimental Methods: 129XOG2 mouse embryonic fibroblasts were seeded into several 24-well cell culture plates and subjected to rapid chemical reprogramming. Every two days, each small molecule or growth factor added to the culture medium at that stage was removed from three wells to examine the effect of removing the small molecule or growth factor at that stage on reprogramming efficiency. On day 12, the resulting induced pluripotent stem cell colonies were counted.
[0194] The results are shown in Figure 1. The vertical axis "iPSC clone number" in Figure 1B represents the number of induced pluripotent stem cell clones that can be formed per 10,000 initial cells. "All" is a positive control, indicating that when the chemical reprogramming factor combination of the present invention is used, approximately 90 induced pluripotent stem cell clones can be formed per 10,000 initial cells. After multiple experiments, approximately 40-90 induced pluripotent stem cell clones can be formed per 10,000 initial cells.
[0195] The tabular data of Figure 1B is shown in Table 2 below:
[0196] Table 2
[0197] The results showed that small molecules CCT129202, BML-277, TSA, DMH1, AZD9291 mesylate, SGC-CBP30, TMP269, Citarinostat, and WS6 could effectively improve the efficiency of chemical reprogramming.
[0198] In addition, the results of Figures 1C and 1D show that iPSC clones have gradually emerged on days 6-7 of FCR, suggesting that the method of the present invention can complete chemical reprogramming with high efficiency on day 7.
[0199] 1.2 Effect of small molecule concentration on results
[0200] Using the rapid chemical reprogramming (FCR) method of the present invention, experiments have shown that the suitable ranges of the small molecule concentrations of the present invention in different rapid chemical reprogramming culture media are as follows:
[0201] SR11237: 0.05-0.5 μM;
[0202] CD3254: 0.05-0.5 μM;
[0203] CCT129202: 0.2-2 μM;
[0204] R406: 0.5-2 μM;
[0205] DMH1: 0.1-5 μM;
[0206] BML-277: 5-20 μM;
[0207] AZD9291 mesylate: 1-5 μM;
[0208] TSA: 5-20nM;
[0209] SGC-CBP30: 0.5-5 μM;
[0210] Citarinostat: 1-3 μM;
[0211] TMP269: 1-10 μM;
[0212] WS6: 0.1-2 μM.
[0213] Identification of iPSCs obtained in Example 2
[0214] Experimental method: (1) Mouse embryonic fibroblasts (MEFs) with a genetic background of 129XOG2 were cultured at a rate of 2.5×10 5 Cells were seeded into 6-well cell culture plates at a density of 100 cells / well and cultured overnight in MEF medium at 21% O2, 5% CO2, and 37°C.
[0215] (2) One day later, the cell culture medium was replaced with the rapid chemical reprogramming 0-2 day medium, which was recorded as reprogramming day 0.
[0216] (3) On the second day of reprogramming, the cell culture medium was replaced with the rapid chemical reprogramming 2-4 day medium.
[0217] (4) On the 4th day of reprogramming, the cell culture medium was replaced with the rapid chemical reprogramming 4-6 day medium, and the medium was renewed on the 5th day.
[0218] (5) On the 6th day of reprogramming, the cell culture medium was replaced with the rapid chemical reprogramming 6-8 day medium, and the medium was renewed on the 7th day.
[0219] (6) On the 8th day of reprogramming, the cell culture medium was replaced with the rapid chemical reprogramming 8-10 day medium.
[0220] (7) On the 10th day of reprogramming, the cell culture medium was replaced with the rapid chemical reprogramming 10-12 day medium.
[0221] (8) On the 12th day of reprogramming, the number of pluripotent stem cell clones was counted under a microscope based on GFP fluorescence.
[0222] The clone morphology and pOct4-GFP expression of the obtained iPSCs were observed.
[0223] As shown in Figure 2A, iPSCs formed arch-shaped clones similar to mouse embryonic stem cells and widely expressed pOct4-GFP. Subsequently, immunofluorescence staining and RT-qPCR techniques were used to detect the protein and mRNA expression levels of the target markers, respectively. As shown in Figures 2B and 2C, iPSCs highly expressed markers such as Oct4, Sox2, Rex1, and Nanog, which were close to the levels of mouse embryonic stem cells. Furthermore, RNA-seq technology was used to detect the expression of all genes in the cells. As shown in Figure 2D, the global gene expression pattern of iPSCs was highly similar to that of mouse embryonic stem cells, but showed significant differences from mouse embryonic fibroblasts. The overall results demonstrated that iPSCs and mouse embryonic stem cells are highly similar at the molecular level.
[0224] The results showed that the obtained iPSCs were similar to the original mouse iPSCs and expressed the following markers: Oct4, Sox2, Rex1, and Nanog.
[0225] Example 3 Application on mouse cells of other genetic backgrounds and types
[0226] The method of the present invention can be used for rapid chemical reprogramming of mouse embryonic fibroblasts with other genetic backgrounds (129XC57 MEF, CF1 MEF) and other types of mouse cells (MLF, MDF).
[0227] The experimental methods were the same as above. Immunofluorescence staining images of iPSC cell lines derived from mouse embryonic fibroblasts of other genetic backgrounds (129XC57 MEF, CF1 MEF) by rapid chemical reprogramming are shown in Figure 3.
[0228] Figure 4 shows immunofluorescence staining images of iPSC cell lines derived from mouse lung fibroblasts (MLF) of adult mice and dorsal fibroblasts (MDF) of embryonic day 18.5 mice by rapid chemical reprogramming.
[0229] The results showed that mouse embryonic fibroblasts from other genetic backgrounds (129XC57 MEFs and CF1 MEFs) could also be reprogrammed into iPSCs using the rapid chemical reprogramming technique, demonstrating that the technique is not limited by cell genetic background. Mouse lung fibroblasts and mouse dorsal fibroblasts could also be reprogrammed into iPSCs using the rapid chemical reprogramming technique, demonstrating its applicability to a wide range of cell types.
[0230] discuss
[0231] The method of the present invention utilizes mice as a model animal and mouse embryonic fibroblasts for experiments. In addition to using mouse embryonic fibroblasts, the method of the present invention can also be used for rapid chemical reprogramming of other types of mouse cells, including mouse dorsal fibroblasts (MDF) and mouse lung fibroblasts (MLF). Specifically, the method of the present invention can be used for rapid chemical reprogramming of mouse embryonic fibroblasts of various genetic backgrounds (129XOG2 MEF, 129XC57 MEF, CF1 MEF).
[0232] The small molecule combination of the present invention can promote transcription factor-induced reprogramming and has a facilitating effect on chemical reprogramming of human cells. Therefore, it can be further extended to human embryonic fibroblasts, thereby establishing the induction of reprogramming of human iPSCs.
[0233] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above teachings of the present invention, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the claims appended hereto.
Claims
1. A chemical reprogramming accelerator, characterized in that: The chemical reprogramming promoter is selected from the following group A: (A1) SR11237; (A2) CD3254; (A3) CCT129202; (A4) R406; (A5) DMH1; (A6) BML-277; (A7) AZD9291 mesylate; (A8) TSA; (A9) SGC-CBP30 (A10) Citarinostat; (A11) TMP269; (A12) WS6; (A13) any combination of (A1) to (A12).
2. The chemical reprogramming accelerator according to claim 1, characterized in that The chemical reprogramming promoter is a compound selected from the following group: (1) SR11237, CD3254; (2) CCT129202, R406; (3) DMH1, BML-277, AZD9291 mesylate, TSA, SGC-CBP30, Citarinostat; (4) DMH1, BML-277, AZD9291 mesylate, TSA, TMP269; or (5) WS6.
3. Use of a chemical reprogramming accelerator, characterized in that: For preparing a reagent or kit for converting fibroblasts into induced pluripotent stem cells; wherein the chemical reprogramming promoter is selected from the following group: (A1) SR11237; (A2) CD3254; (A3) CCT129202; (A4) R406; (A5) DMH1; (A6) BML-277; (A7) AZD9291 mesylate; (A8) TSA; (A9) SGC-CBP30 (A10) Citarinostat; (A11) TMP269; (A12) WS6; (A13) Any combination of (A1) to (A12).
4. The use according to claim 3, characterized in that The fibroblasts are mammalian fibroblasts; preferably, they are fibroblasts from mice, rats, rabbits, monkeys, or humans.
5. The use according to claim 3, characterized in that The fibroblasts are mouse fibroblasts, preferably mouse dorsal fibroblasts (MDF), mouse lung fibroblasts (MLF), mouse liver fibroblasts, mouse heart fibroblasts or mouse embryonic fibroblasts (MEF).
6. A culture medium for chemical reprogramming, characterized in that It comprises basic culture components and a chemical reprogramming promoter, wherein the chemical reprogramming promoter is selected from the following group A: (A1) SR11237; (A2) CD3254; (A3) CCT129202; (A4) R406; (A5) DMH1; (A6) BML-277; (A7) AZD9291 mesylate; (A8) TSA; (A9) SGC-CBP30 (A10) Citarinostat; (A11) TMP269; (A12) WS6; (A13) any combination of (A1) to (A12).
7. The culture medium according to claim 6, characterized in that The culture medium for chemical reprogramming also includes other growth factors and compounds, including but not limited to: β-mercaptoethanol, basic fibroblast growth factor, CHIR99021, 616452, Forskolin, AM580, EPZ004777, VPA, 5-aza-dC, SGC0946, mouse leukemia inhibitory factor, and PD0325901.
8. A method for reprogramming fibroblasts into induced pluripotent stem cells, characterized in that: include: (S1) providing a fibroblast; (S2) pre-culturing the fibroblasts in (S1) using a first reprogramming cell culture medium to obtain first intermediate cells; (S3) culturing the first intermediate cells using a second reprogramming cell culture medium to obtain second intermediate cells; (S4) culturing the second intermediate cells using a third reprogramming cell culture medium to obtain third intermediate cells; (S5) culturing the third intermediate cells using a fourth reprogramming cell culture medium to obtain fourth intermediate cells; and (S6) amplifying the fourth intermediate cells to obtain induced pluripotent stem cells.
9. The method according to claim 8, characterized in that (S1), the density of the fibroblasts is 10 4 -10 6 cells / well.
10. The method according to claim 8, characterized in that In (S2), the first reprogramming cell culture medium comprises a compound selected from the group consisting of SR11237 and CD3254.
11. The method according to claim 8, characterized in that In (S2), the culture time is t1, and t1 is 0-3 days; preferably 0.5-2 days.
12. The method according to claim 8, characterized in that (S3), the second reprogramming cell culture medium further comprises a compound selected from the group consisting of basic fibroblast growth factor, CHIR99021, 616452, Forskolin, AM580, SR11237, CD3254, and VPA.
13. The method according to claim 8, characterized in that (S3), the culture time is t2, and t2 is 0-3 days; preferably 0.5-2 days.
14. The method according to claim 8, characterized in that (S4), the third reprogramming cell culture medium comprises a compound selected from the group consisting of DMH1, BML-277, AZD9291 mesylate, TSA, SGC-CBP30, and Citarinostat.
15. The method according to claim 14, characterized in that (S4), the concentration of DMH1 is 0.1-5 μM; The concentration of BML-277 was 5-20 μM; The concentration of AZD9291 mesylate was 1-5 μM; The concentration of TSA was 5-20 nM; The concentration of SGC-CBP30 was 1-10 μM; The concentration of Citarinostat was 1-3 μM.
16. The method according to claim 8, characterized in that (S5), the fourth reprogramming cell culture medium comprises a compound selected from the group consisting of DMH1, BML-277, AZD9291 mesylate, TSA, and TMP269.
17. The method according to claim 8, characterized in that In (S4), the fibroblasts are mouse fibroblasts, preferably mouse dorsal fibroblasts (MDF), mouse lung fibroblasts (MLF), mouse liver fibroblasts, mouse cardiac fibroblasts or mouse embryonic fibroblasts (MEF).
18. An embryonic stem cell prepared by the method of claim 8, characterized in that: The cells expressed the following markers: Oct4, Sox2, Rex1, Nanog.
Citation Information
Patent Citations
Biologically related substances modified by multifunctional H-type polyethylene glycol derivative
CN104530413A
Pluripotent stem cell inducer and application thereof
CN108998417A
Induced totipotent stem cell and preparation method thereof
CN115725495A
Application of EGCG (epigallocatechin gallate) combined CHK2 inhibitor in improvement of egg maturation or embryonic development
CN116024162A
Utilizing CD3254 to activate RNA exons to drive somatic cell reconstruction pluripotency
CN116574674A
Cited By
Cell factor-free human pluripotent stem cell culture medium
CN122326517A
